Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Double-blind, Randomized, Parallel Group, Placebo Controlled Efficacy and Safety Study of Oral CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT02385760 is registered in ClinicalTrials.gov with Celtaxsys, Inc. as lead sponsor.

NCT NCT02385760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02385760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Double-blind, Randomized, Parallel Group, Placebo Controlled Efficacy and Safety Study of Oral CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
Lead sponsor
Celtaxsys, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2015
Completion date
August 31, 2016
Enrollment
124 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris